-0.00346020761245675 -0.00346020761245675 -0.00657439446366774 -0.0069204152249135 -0.00346020761245675 -0.00173010380622837 -0.00346020761245675 -0.0188581314878892
Sign Up Today X
Thanks for submitting the form.
Stockreport

Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters]

Biogen Inc. (BIIB)  More Company Research Source: Reuters
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Biogen beats profit estimates on demand for multiple sclerosis drug (Reuters) - Biogen Inc beat Wall Street expectations for quarterly profit on Thursday, driven by demand for its top-selling multiple sclerosis drug, Tecfidera. Tecfidera revenue rose 4.5% to $1.16 billion, ahead of Street estimates of $1.12 billion and at a time when the drug faces patent challenges and increasing competition from newer treatments, including Roche Holding AG’s Ocrevus. Sales of Spinraza, the first approved treatment for spinal muscular atrophy, rose to $543.2 million, but missed the average analysts’ estimate of $549 million, according to Refinitiv data. The company said it expects 2020 full-year adjusted profit to be in the range of $31.50 per share and $33.50 per share. Analysts on average were expecting $33.03 per share. Net income attributable to the company rose to $1.44 billion, or $8.08 per share, in the quarter ended Dec. 31, from $946.8 million, or $4.73 per share, a year earlier when it paid [Read more]
IMPACT SNAPSHOT EVENT TIME: BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BIIB alerts
from News Quantified
BIIB
NEWS
BIIB
Earnings
BIIB
Analyst Actions
BIIB
SEC Filings
Stockreport

Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters]

Biogen Inc.  (BIIB) 
More Company Research Source: Reuters
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Biogen beats profit estimates on demand for multiple sclerosis drug (Reuters) - Biogen Inc beat Wall Street expectations for quarterly profit on Thursday, driven by demand for its top-selling multiple sclerosis drug, Tecfidera. Tecfidera revenue rose 4.5% to $1.16 billion, ahead of Street estimates of $1.12 billion and at a time when the drug faces patent challenges and increasing competition from newer treatments, including Roche Holding AG’s Ocrevus. Sales of Spinraza, the first approved treatment for spinal muscular atrophy, rose to $543.2 million, but missed the average analysts’ estimate of $549 million, according to Refinitiv data. The company said it expects 2020 full-year adjusted profit to be in the range of $31.50 per share and $33.50 per share. Analysts on average were expecting $33.03 per share. Net income attributable to the company rose to $1.44 billion, or $8.08 per share, in the quarter ended Dec. 31, from $946.8 million, or $4.73 per share, a year earlier when it paid [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS